Prostate Cancer

>

Latest News

The Evolving Landscape of Prostate Cancer Management
The Evolving Landscape of Prostate Cancer Management

October 28th 2024

Maha Hussain, MD, FACP, FASCO, spoke about BRCA testing and ctDNA as diagnostic tools and PSMA-imaging and -targeted approaches in prostate cancer.

Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.
Darolutamide/ADT Improves rPFS in Metastatic HSPC

October 13th 2024

Retrospective analysis data on apalutamide vs enzalutamide in patients with prostate cancer were consistent with findings from the phase 3 TITAN trial.
Apalutamide Significantly Improves OS Vs Enzalutamide in Metastatic CSPC

October 11th 2024

Detailed results from the phase 3 TALAPRO-2 trial will be submitted for presentation at a future medical meeting and shared with global health authorities.
Talazoparib/Enzalutamide Combo Prolongs Survival in Metastatic CRPC

October 10th 2024

Phase 2 data support further evaluation of nivolumab plus standard radiotherapy in patients with Gleason grade 5 prostate cancer.
Nivolumab/RT Improves Biochemical Recurrence Outcomes in Prostate Cancer

October 4th 2024

Latest CME Events & Activities

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

View More

18th Annual New York GU Cancers Congress™

March 28-29, 2025

Register Now!

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

<1
...
6162636465